Statins for the Prevention of Stroke: A Meta-Analysis of Randomized Controlled Trials

Wen Wang, Bo Zhang*
Department of Neurosurgery, First Affiliated Hospital of Dalian Medical University, Dalian, PR China

Abstract

Background: Stroke is a frequently encountered clinical event that has a detrimental impact on the quality of life. Evidence has increasingly shown that statins can substantially reduce the risk of coronary heart disease. However, it remains to be determined whether statins are definitively effective in preventing stroke.

Methods: We systematically searched the PubMed, Embase, and Central databases for studies that compared the effects of statins and placebo in patients at high risk for stroke. The outcome measures were overall incidence of stroke, incidence of fatal stroke, and incidence of hemorrhagic stroke.

Results: Eighteen randomized controlled trials satisfied all the inclusion criteria for the meta-analysis. The analysis revealed that statins reduced the overall incidence of stroke than placebo (odds ratio [OR]: 0.80; 95% confidence interval [CI]: 0.74–0.87; P < 0.00001). In particular, statins showed efficacy in reducing the incidence of fatal stroke (OR: 0.90; 95% CI: 0.67–1.21; P = 0.47) and hemorrhagic stroke (OR: 0.87; 95% CI: 0.60–1.25; P = 0.45). On the contrary, they were found to increase the overall incidence of stroke (OR: 1.12; 95% CI: 0.89–1.41; P = 0.32) and fatal stroke (OR: 1.37; 95% CI: 0.93–2.03; P = 0.11) in renal transplant recipients and patients undergoing regular hemodialysis.

Conclusion: The results of this analysis suggest that statins may be beneficial in reducing the overall incidence of stroke and may decrease the risk of fatal stroke and hemorrhagic stroke. However, statins should be used with caution in patients with a history of renal transplantation, regular hemodialysis, transient ischemic attack, or stroke. Further analyses should focus on multicentre, double-blind, placebo-controlled randomized trials with data stratification according to the nature of primary diseases and dose–effect relationship, to clarify the benefits of statins in protection against stroke.

Introduction

Stroke leads to disturbances in the blood supply to the brain, which can lead to the rapid deterioration of brain function. On the basis of etiology, stroke can be broadly classified into two types: ischemic and hemorrhagic; it is a heterogeneous condition that involves several causative factors in high-risk populations [1], such as patients with coronary heart disease (CHD), diabetes mellitus, and hypertension. A salient feature of stroke is that the type of stroke is not correlated with the prognosis of the patient [2].

Many studies have indicated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) reduce cardiovascular mortality by bringing about a reduction in the serum low-density lipoprotein (LDL) levels; this reduction has been shown to substantially lower the risk of CHD [3–6]. Further, several large-scale clinical trials have been conducted to evaluate the efficiency of statins in the primary and secondary prevention of atherosclerosis and stroke [7–9]. While some of these trials have shown the beneficial effect of statins in stroke prevention, others have not. This discrepancy in the currently available evidences leads to uncertainty regarding the effect of statins on the prevention of stroke in general and fatal stroke and hemorrhagic stroke in particular.

In the light of the prevalent confusion regarding the efficacy of statins in various high-risk populations, we sought to conduct a meta-analysis of randomized clinical trials (RCTs) evaluating the efficacy of statins in the primary and secondary prevention of stroke in high-risk populations.

Methods

Search strategy

In this meta-analysis, we conducted a thorough search of the PubMed, Embase, and Central databases for the reports of all the RCTs conducted up to October 2012 on the comparison of statins with placebo in the prevention of stroke, without any language restriction. The following search terms were used in various combinations: “stroke,” “pravastatin,” “lovastatin,” “atorvastatin,” “simvastatin,” “fluvastatin,” “cerivastatin,” “rosuvastatin,” “pitavastatin,” “HMG-CoA reductase inhibitor,” and “statins.” To account for both published and unpublished studies, we performed a cited references search by using Web of Science, checked the reference lists of the identified relevant trials, and contacted the authors of the respective papers and investigators. The primary endpoint of the analysis was the overall incidence of

Citation: Wang W, Zhang B (2014) Statins for the Prevention of Stroke: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 9(3): e92388. doi:10.1371/journal.pone.0092388

Editor: Michael Fehlings, University of Toronto, Canada

Received May 10, 2013; Accepted February 21, 2014; Published March 18, 2014

Copyright: © 2014 Wang, Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: zhangbodl@126.com
stroke, incidence of fatal stroke, and incidence of hemorrhagic stroke. The data extraction was independently performed by WW and BZ, and differences in opinion were resolved through discussion.

Inclusion criteria
Studies were included in the meta-analysis if they fulfilled the following criteria: (1) enrolled subjects had high risk of stroke due to prevalent conditions (CHD, diabetes mellitus, hypertension, myocardial ischemia, and hypercholesterolemia) and were of mean age ≥ 50 y; (2) the studies were RCTs conducted on humans; (3) the dosage of statin therapy was specified; (4) the details regarding the type of stroke, including fatal stroke and hemorrhagic stroke, were reported; and (5) the incidence of stroke in the study population was specified or could be calculated.

Subgroup analysis
In order to specifically evaluate the efficacy of statins in patients with end-stage renal disease, a subgroup analysis was performed on trials that included only renal transplant recipients or patients undergoing regular hemodialysis.

Quality assessment
The risk of bias in each study was evaluated by using the Cochrane Collaboration’s tool following the instructions given in the Cochrane Handbook for Systematic Reviews. The assessment was made across six domains: sequence generation, allocation concealment, blinding, incomplete data outcomes, selective outcome reporting, and other causes of bias. We studied the influence of the methodological quality of the trials on their results by reviewing the reported randomization protocol and follow-up procedures adopted in each trial.

Figure 1. Flow chart indicating the selection process for this meta-analysis.
doi:10.1371/journal.pone.0092388.g001
### Table 1. Baseline characteristics of included studies.

| STUDY ID                        | AGE   | FEMALE % | TREATMENT | Follow-up year | N(I/C)       | Overall Stroke(OS) | Fatal Stroke(FS) | Hemorrhagic Stroke(HS) |
|---------------------------------|-------|----------|-----------|----------------|--------------|--------------------|-------------------|------------------------|
| Athyros VG et al. 2002 [10]     | 59 y  | 22%      | Atorvastatin 10-80 | 3 y           | 800/800      | 9/17               | ND                | ND                     |
| Koren MJ et al. 2004 [11]       | 61 y  | 17%      | Simvastatin 10-80 | 4.3 y         | 1217/1225    | 35/39              | ND                | ND                     |
| Knopp RH et al. 2006 [12]       | 61 y  | 34%      | Simvastatin 10 | 4 y           | 1211/1199    | 34/38              | ND                | ND                     |
| Sever PS et al. 2007 [13]       | 63 y  | 19%      | Atorvastatin 10  | 3.3 y         | 5168/5163    | 110/139            | ND                | ND                     |
| White HD et al. 2000 [14]       | 62 y  | 17%      | Pivastatin 40   | 6 y           | 4512/4502    | 169/204            | ND                | 9/18                   |
| Nakamura H et al. 2006 [15]     | 58 y  | 69%      | Simvastatin 10-20| 5.3 y         | 3686/3956    | 50/62              | ND                | 16/14                  |
| ALLHAT 2002 [16]                | 66 y  | 49%      | Pivastatin 40   | 4.8 y         | 5710/5185    | 209/231            | 53/56             | ND                     |
| Shepherd J et al. 2002 [17]     | 75 y  | 52%      | Pivastatin 40   | 3.2 y         | 2891/2913    | 135/131            | 22/14             | ND                     |
| Hitman GA et al. 2007 [18]      | 62 y  | 32%      | Atorvastatin 10 | 3.9 y         | 1428/1410    | 21/39              | 1/7               | ND                     |
| Amarenco P et al. 2006 [19]     | 63 y  | 40%      | Simvastatin 80  | 4.9 y         | 2365/2366    | 265/311            | 24/41             | 55/33                  |
| Plehn JF et al. 1999 [20]       | 59 y  | 14%      | Pivastatin 40   | 5 y           | 2081/2078    | 52/76              | 5/1               | 2/6                    |
| HPSI 2003 [21]                  | 65 y  | 25%      | Pivastatin 40   | 5 y           | 10269/10267  | 444/585            | 96/119            | 51/53                  |
| Waters DD et al. 2002 [22]      | 65 y  | 35%      | Atorvastatin 80 | 0.3 y         | 1538/1548    | 13/25              | 3/2               | 0/3                    |
| Kjekshus J et al. 2007 [23]     | 73 y  | 24%      | Simvastatin 10  | 2.7 y         | 2514/2497    | 103/115            | 14/11             | 15/9                   |
| Everett BM et al. 2010 [24]     | 66 y  | 38%      | Rosuvastatin 20 | 1.9 y         | 8901/8901    | 33/64              | 3/6               | 6/9                    |
| Wanner C et al. 2005 [25]       | 66 y  | 46%      | Simvastatin 20  | 4 y           | 619/636      | 60/45              | 27/13             | 3/5                    |
| Fellstrom BC et al. 2009 [26]   | 64 y  | 38%      | Simvastatin 10  | 3.2 y         | 1389/1384    | 93/81              | 40/36             | 25/21                  |
| Abedini S et al. 2009 [27]      | 50 y  | 34%      | Fluvastatin 80  | 6.7 y         | 1050/1052    | 77/83              | 21/17             | 10/17                  |

ND: No Data; I/C: Intervention/Control.

doi:10.1371/journal.pone.0092388.t001
**Table 2. GRADE profile evidence of the included studies.**

| Quality assessment | No of patients | Effect | Quality | Importance |
|--------------------|----------------|--------|---------|------------|
| **Overall Stroke (follow-up mean 4 years)** | | | | |
| No of studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations | Statins | Control | Relative (95% CI) | Absolute |
| 18 Randomized trials No serious risk of bias No serious inconsistency No serious indirectness No serious imprecision Reporting bias | 1912/56989 (3.4%) | 2.285/57092 (4%); 4.1% | OR 0.84 (0.76 to 0.92) | 6 fewer per 1000 (from 3 fewer to 9 fewer); 6 fewer per 1000 (from 3 fewer to 10 fewer) | MODERATE | IMPORTANT |
| **Fatal Stroke (follow-up mean 3.8 years)** | | | | |
| No of studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations | Statins | Control | Relative (95% CI) | Absolute |
| 12 Randomized trials No serious risk of bias No serious inconsistency No serious indirectness No serious imprecision Reporting bias | 309/40215 (0.8%) | 3.23/40237 (0.8%); 0.8% | OR 1.03 (0.79 to 1.35) | 0 more per 1000 (from 2 fewer to 3 more); 0 more per 1000 (from 2 fewer to 3 more) | MODERATE | CRITICAL |
| **Hemorrhagic Stroke (follow-up mean 4 years)** | | | | |
| No of studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations | Statins | Control | Relative (95% CI) | Absolute |
| 10 Randomized trials No serious risk of bias No serious inconsistency No serious indirectness No serious imprecision Reporting bias | 137/36739 (0.4%) | 1.55/36831 (0.4%); 0.4% | OR 0.88 (0.67 to 1.15) | 1 fewer per 1000 (from 1 fewer to 1 more); 0 fewer per 1000 (from 1 fewer to 1 more) | MODERATE | CRITICAL |

*doi:10.1371/journal.pone.0092388.t002*
The quality of evidence was rated using the Grade of Recommendation, Assessment, Development, and Evaluation (GRADE) approach by using the GRADEpro software (version 3.6). As per the GRADE approach, the evidences were graded into the following levels of quality according to the likelihood of change in the estimate of the effect in the light of further research: (1) high quality, if the estimate was extremely unlikely to change; (2) moderate quality, if the estimate was moderately likely to change; (3) low quality, if the estimate effect was highly likely to change; (4) very low quality, if the estimate appeared to be extremely uncertain.

Statistical analysis
The overall incidence of stroke was expressed in dichotomous variables, and the results were expressed as odds ratio (OR) with 95% confidence interval (CI). Data on the incidence of fatal stroke and hemorrhagic stroke were available in 12 and 11 trials, respectively. The pooled estimate of efficacy was calculated using the Mantel-Haenszel method, and the random-effects model was used because various types and strengths of statins were used in the analyzed studies. Significant heterogeneity was defined at P < 0.05. Heterogeneity was assessed using the I² statistic: when I² was < 25%, heterogeneity was considered absent; when I² was 25–50%, heterogeneity was considered low; when I² was 50–75%, heterogeneity was considered moderate; and when I² was > 75%, heterogeneity was considered high. All statistical analyses were performed using Review Manager 5.2 (version 5.2.4; http://ims.cochrane.org/revman).

Results

Literature search
The initial database search retrieved 1787 studies (335 from PubMed, 748 from Embase, 704 from Central) that were limited to humans, RCTs, and published before October 2012. After eliminating duplicate entries, the number of entries was reduced to 1521. Finally, after applying all the inclusion criteria, 18 RCTs, conducted on 114,081 subjects in all, were selected for the analysis (Figure 1).

Study characteristics
The salient features of the 18 selected studies [10–27] are summarized in Table 1. The studies were published between 1999 and 2010, included 1255 to 20536 subjects each, and had a mean follow-up duration of 4 y. Various statins were investigated in these trials: rosuvastatin, fluvastatin, atorvastatin, pravastatin, and simvastatin. The mean serum level of LDL recorded in the studies was 136 mg/dl.

All the studies were conducted on populations at high risk of stroke, including those with CHD, diabetes mellitus, hypertension and myocardial ischemia. Additionally, one RCT [27] included renal transplant recipients, and two RCTs [25,26] included patients undergoing regular hemodialysis. A subgroup analysis was conducted with these three RCTs. In addition, patients in one of the RCTs [19] had history of stroke or transient ischemic attack (TIA) within the past one to six months, and statins were used in this population for the secondary prevention of stroke.

GRADE evidence profile
All the included RCTs had the same endpoints, which were overall incidence of stroke, incidence of fatal stroke, and incidence of hemorrhagic stroke. The GRADE evidence profiles for upgrading or downgrading each outcome level are shown in Table 2.

Risk of bias
The risk of bias in the included studies is summarized through a graph (Figure 2) and summary (Figure 3). The 18 trials were conducted across eight different countries, namely, USA, UK, Norway, Sweden, Greece, Japan, Germany, and New Zealand, and were mostly based in hospitals or clinics. Only four of the included trials [16,17,23,25] had adequate allocation concealment. All the included trials were considered to have adequate sequence generation because they were essentially randomized in nature. The reports of 12 trials did not describe the method used for generating the allocation sequence. One trial [10] report indicated that patients were randomly allocated to the intervention or placebo group at the outpatient clinic, and therefore, the risk of bias for random sequence generation was considered to be high. While most trials reported blinding of outcome assessment, that of participants, personnel, and outcome assessment was reported only in the case of three [10,19,25] trials. One study [16] was a nonblinded trial, and the risk of bias due to inadequate blinding of participants and personnel was considered high in this case. In most of the selected RCTs, participant flow and important outcomes were reported; therefore, we assessed the incomplete outcome data bias and considered all trials to be of low risk of
selective reporting. In one trial [22], the duration of follow up was only 0.3 y, which made the long-term effect of statins on stroke incidence unclear; therefore, the risk of bias due to other causes was considered to be high for that trial.

Overall stroke incidence
The overall incidence of stroke was indicated in all the trial reports. The pooled percentages in the intervention and placebo groups were 3.36% and 4%, respectively. The result of the meta-analysis of all the included studies showed a significant reduction in the incidence of overall stroke in patients treated with statins (OR: 0.80; 95% CI: 0.74–0.87; P<0.00001; Figure 4).

The trial by Amarenco et al. [19] included patients with history of stroke or TIA. Pooled results obtained after excluding this study did not differ significantly from those obtained after its inclusion (OR: 0.80; 95% CI: 0.72–0.87; P<0.00001), and neither did the heterogeneity (I² = 28%, heterogeneity, P = 0.15).

Fatal stroke incidence
Nine trial reports provided data on the incidence of fatal stroke [16–24] among 74,322 patients (Table 1). Meta-analysis using the random-effects model showed that statin treatment induced no significant reduction in the incidence of fatal stroke (OR: 0.90; 95% CI: 0.67–1.21; P = 0.47; Figure 5) and that heterogeneity among the trials was low (I² = 40%; heterogeneity, P = 0.10).

Hemorrhagic stroke incidence
Data regarding the efficiency of statins in the prevention of hemorrhagic stroke were available for 11 RCTs. Pooled analysis of data from 7 [14,15,20–24] of these studies, using the random-effects model, revealed that statins did not significantly reduce the incidence of hemorrhagic stroke (OR: 0.87; 95% CI: 0.60–1.25; P = 0.45; Figure 6) and had low statistical heterogeneity (I² = 26%; heterogeneity, P = 0.23). Analysis including the study performed by Amarenco et al. [19] showed a different result (OR: 0.98; 95% CI: 0.67–1.43; P = 0.91), with low heterogeneity (I² = 49%; heterogeneity, P = 0.06).

Subgroup analysis
Subgroup analysis was performed on the three trials [25–27] conducted on renal transplant recipients or patients undergoing regular hemodialysis, by using the random-effects model. The analysis revealed the following: statins reduced the overall incidence of stroke, although this reduction had low statistical significance (OR: 1.12; 95% CI: 0.89–1.41; P = 0.32; Figure 4); statins may, in fact, increase the incidence of fatal stroke (OR: 1.37; 95% CI: 0.93–2.03; P = 0.11; Figure 5); and statins had a beneficial effect on the incidence of hemorrhagic stroke (OR: 0.87; 95% CI: 0.53–1.42; P = 0.58; Figure 6), but with low statistical significance.

Publication bias
Publication bias was assessed using the funnel plot, and the results indicated that the risk of significant bias was low (Figure 7).

Discussion
Current evidences indicate that statins can reduce the incidence of cardiovascular disease via various mechanisms, which include reduced lipid and platelet aggregation, improved endothelial function, anti-inflammation activity, and neuroprotective action [28–31]. Through this meta-analysis, we sought to determine whether statins can indeed prevent stroke, especially fatal stroke and hemorrhagic stroke.

Our analysis of 18 RCTs revealed that statins did, in fact, significantly reduce the overall incidence of stroke. Further, statins
were found to be effective in the prevention of fatal stroke, although this effect was not statistically significant. On the contrary, three RCTs [25-27] showed that statins may potentially increase the incidence of overall stroke and fatal stroke in patients with a history of renal transplantation, regular hemodialysis, TIA, or stroke, but not significantly. Since this finding was not statistically significant, further investigations are warranted to confirm this. Nevertheless, statins have been previously shown to protect against kidney disease through various immunomodulatory mechanisms [7-9,32]. Therefore, when treating kidney transplant recipients or patients undergoing regular hemodialysis, clinicians should carefully assess the requirement and the dosage of statins administered in relation to the patient's renal function.

This meta-analysis revealed that the use of statins may decrease the incidence of hemorrhagic stroke, although not in a statistically significant manner. This finding is consistent with previous reports indicating the safety of statins in the prevention of hemorrhagic stroke [33,34]. A study by Amarenco et al. [19] on the secondary prevention of stroke revealed that patients treated with statins had a significantly greater frequency of hemorrhagic stroke (55 events) than those treated with placebo (33 events), thereby indicating that the incidence of hemorrhagic stroke in the intervention group was 67% (95% CI: 1.09-2.60). Subsequent analysis revealed that the incidence of hemorrhagic stroke was particularly high in older male patients who had a history of hypertension or stroke [35]. This may be explained by the fact that statins are reported to cause vascular dilatation with rising levels of nitric oxide in the vascular endothelium, which has been implicated in the pathogenesis of hemorrhagic stroke. This may render statins unsuitable for the secondary prevention of stroke.

With regard to the quality of evidence, evaluation using the GRADE system indicated that the data from the included studies were of moderate quality. Since all the 18 included RCTs yielded important outcomes, all trials were to be at low risk of selective reporting.

Our findings should be interpreted in the light of a few limitations. This meta-analysis included only three RCTs comprising renal transplant recipients or patients undergoing regular hemodialysis and only one trial comprising patients with a history of TIA or stroke. This could have led to an underestimation or overestimation of the true incidence of stroke among the analyzed population. Further, we could not account for the impact of the type of coexisting primary diseases (e.g., CHD, diabetes mellitus, hypertension etc.), because the evaluated reports did not contain separate records for the various conditions. Another drawback is that from the current evidences, we were unable to analyze the

| Study or Subgroup | Intervention | Control | Odds Ratio | Odds Ratio |
|-------------------|-------------|---------|------------|------------|
|                  | Events      | Total   | Events     | Total      | M-H, Random, 95% CI | M-H, Random, 95% CI |
| ALLHAT 2002      | 209         | 5170    | 231        | 5185       | 9.1% | 0.90 [0.75, 1.09] |
| Amarenco P et al.2006 | 265 | 2385 | 311        | 2366       | 9.7% | 0.83 [0.70, 0.99] |
| Athyros VG et al.2002 | 9     | 800    | 17         | 800        | 1.2% | 0.52 [0.23, 1.18] |
| Everett BM et al.2010 | 33   | 8901   | 64         | 8901       | 3.7% | 0.51 [0.34, 0.78] |
| Hitzman GA et al.2007 | 21   | 1428   | 39         | 1410       | 2.6% | 0.52 [0.31, 0.90] |
| HPSI ,2002       | 444        | 10269   | 585        | 10267      | 11.6% | 0.75 [0.66, 0.85] |
| Kjekshus J et al.2007 | 103 | 2514   | 115        | 2497       | 6.6% | 0.88 [0.67, 1.16] |
| Knopp RH et al.2006 | 34    | 1211   | 38         | 1199       | 3.2% | 0.88 [0.55, 1.41] |
| Koren MJ et al.2004 | 35    | 1217   | 39         | 1225       | 3.2% | 0.90 [0.57, 1.43] |
| Nakamura H et al.2006 | 50   | 3866   | 62         | 3966       | 4.4% | 0.83 [0.57, 1.20] |
| Plehn JF et al.1998 | 52    | 2081   | 76         | 2078       | 4.7% | 0.68 [0.47, 0.97] |
| Sever PS et al.2007 | 110   | 5168   | 139        | 5163       | 7.1% | 0.79 [0.61, 1.01] |
| Shepherd J et al.2002 | 135  | 2891   | 131        | 2913       | 7.3% | 1.04 [0.81, 1.33] |
| Waters DD et al.2002 | 13   | 1538   | 25         | 1458       | 1.7% | 0.82 [0.52, 1.26] |
| White HD et al.2000 | 169   | 4512   | 204        | 4502       | 6.5% | 0.82 [0.67, 1.01] |
| Subtotal (95% CI) | 53931     | 54020   | 84.3%      |            | 0.80 [0.74, 0.87] |

Total events: 1682
Heterogeneity: Tau² = 0.01; Ch² = 18.38, df = 14 (P = 0.19); I² = 24%
Test for overall effect: Z = 5.20 (P = 0.00001)

2.1.2 Renal

| Study or Subgroup | Intervention | Control | Odds Ratio | Odds Ratio |
|-------------------|-------------|---------|------------|------------|
| Abedini S et al.2009 | 77     | 1050   | 83         | 1052       | 5.4% | 0.92 [0.67, 1.28] |
| Fellström BC et al.2009 | 93   | 1389   | 81         | 1384       | 5.7% | 1.15 [0.85, 1.57] |
| Wanner C et al.2005 | 60    | 619    | 45         | 636        | 4.0% | 1.41 [0.94, 2.11] |
| Subtotal (95% CI) | 3058     | 3072   | 15.1%      |            | 1.12 [0.89, 1.41] |

Total events: 230
Heterogeneity: Tau² = 0.01; Ch² = 2.65, df = 2 (P = 0.27); I² = 25%
Test for overall effect: Z = 0.99 (P = 0.32)

Subtotal (95% CI): 56989
Total events: 2285
Heterogeneity: Tau² = 0.02; Ch² = 30.81, df = 17 (P = 0.02); I² = 45%
Test for overall effect: Z = 3.68 (P = 0.0002)
Test for subarachnoid differences: Ch² = 7.43, df = 1 (P = 0.006); I² = 86.5%

Figure 4. Forest plot for overall stroke incidence.
doi:10.1371/journal.pone.0092388.g004
### Statins for the Prevention of Stroke

#### Figure 5. Forest plot for fatal stroke incidence.

| Study or Subgroup | Intervention Events | Control Events | Odds Ratio | Odds Ratio |
|-------------------|---------------------|----------------|------------|------------|
| ALLHAT.2002       | 53 5170             | 56 5185        | 0.95 [0.65, 1.38] |            |
| Amarenco P et al.2006 | 24 2365           | 41 2368        | 0.58 [0.35, 0.97] |            |
| Everett BM et al.2010 | 3 8901           | 6 8901         | 0.50 [0.12, 2.00] |            |
| Hitman GA et al.2007 | 1 1428            | 7 1410         | 0.14 [0.02, 1.14] |            |
| HPSI.2002         | 96 10269           | 119 10267      | 0.80 [0.61, 1.05] |            |
| Kjekshus J et al.2007 | 14 2514          | 11 2497        | 1.27 [0.67, 2.48] |            |
| Pfehl JF et al.1999 | 5 2081            | 1 2078         | 5.00 [0.58, 42.85] |            |
| Shepherd J et al.2002 | 22 2891           | 14 2913        | 1.59 [0.81, 3.11] |            |
| Waters DD et al.2002 | 3 1538            | 2 1548         | 1.51 [0.25, 9.05] |            |
| Subtotal (95% CI) | 37157 37165        |                | 0.90 [0.67, 1.21] |            |

Total events 221 257
Heterogeneity: Tau² = 0.07; Chi² = 13.32, df = 8 (P = 0.10); I² = 40%

Test for overall effect: Z = 0.72 (P = 0.47)

#### Figure 6. Forest plot for hemorrhagic stroke incidence.

| Study or Subgroup | Intervention Events | Control Events | Odds Ratio | Odds Ratio |
|-------------------|---------------------|----------------|------------|------------|
| Abedini S et al.2009 | 21 1050           | 17 1052        | 1.24 [0.65, 2.37] |            |
| Fellstrom BC et al.2009 | 40 1389         | 36 1384        | 1.11 [0.70, 1.75] |            |
| Wanner C et al.2005 | 27 619            | 13 636         | 2.19 [1.12, 4.28] |            |
| Subtotal (95% CI) | 3058 3072         |                | 1.37 [0.93, 2.03] |            |

Total events 88 66
Heterogeneity: Tau² = 0.03; Chi² = 2.75, df = 2 (P = 0.25); I² = 27%

Test for overall effect: Z = 1.56 (P = 0.11)

Total (95% CI) 40215 40237 100.0%

Test for subgroup differences: Chi² = 2.86, df = 1 (P = 0.09). I² = 65.0%

---

### Figure 5. Forest plot for fatal stroke incidence.

![Forest plot for fatal stroke incidence](https://doi.org/10.1371/journal.pone.0092388.g005)

### Figure 6. Forest plot for hemorrhagic stroke incidence.

![Forest plot for hemorrhagic stroke incidence](https://doi.org/10.1371/journal.pone.0092388.g006)
possible dose–effect relationship for different types of statins. This highlights the need for more multicentre, double-blind, placebo-controlled randomized trials focusing on the nature of the coexisting primary disease and dose–effect relationship.

**Conclusion**

The findings of this meta-analysis indicate that statins may be beneficial in preventing the occurrence of stroke in general. In particular, it may potentially reduce the incidence of fatal stroke and hemorrhagic stroke. However, caution must be exercised when using statins in patients with a history of renal transplantation, regular hemodialysis, TIA, or stroke. Further analyses based on data collected in multicentre, double-blind, placebo-controlled, randomized trials and stratified by primary diseases and dose–effect relationship are warranted to substantiate the findings of this meta-analysis.

**Supporting Information**

Protocol S1 (DOC)
Checklist S1 (DOC)
Search Strategy S1 (DOC)

**Author Contributions**

Conceived and designed the experiments: BZ WW. Performed the experiments: BZ WW. Analyzed the data: BZ WW. Contributed reagents/materials/analysis tools: BZ WW. Wrote the paper: WW.

**References**

1. Mohr JP, Albers GW, Amarenco P, Babikian VL, Biller J, et al. (1997) American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Etiology of stroke. Stroke 28: 1501–1506.
2. Kent DM (2006) Stroke—an equal opportunity for the initiation of statin therapy. N Engl J Med 355: 613–615.
3. Robinson JG, Smith B, Maheshwari N, Schrott H (2005) Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46: 1855–1862.
4. Calabro P, Yeh ET (2005) The pleiotropic effects of statins. Curr Opin Cardiol 20: 541–546.
5. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, et al. (2003) Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53: 743–751.
6. Grundy SM (1997) Cholesterol and coronary heart disease. The 21st century. Arch Intern Med 157: 1177–1184.
7. (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.
8. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349–1357.
9. Heart Protection Study Collaborative G (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.
10. Athyros VG, Papageorgiou AA, Mercoucris BR, Athyrou VV, Symeonidis AN, et al. (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18: 220–228.
11. Koren MJ, Humminghake DB, Investigators A (2004) Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 44: 1772–1779.
12. Knopp RH, d’Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29: 1478–1485.
13. Sever PS, Poulier NR, Dahlöf B, Wedel H, Beevers G, et al. (2000) The Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering arm: extended observations 2 years after trial closure. Eur Heart J 21: 499–508.
14. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, et al. (2000) Pravastatin therapy and the risk of stroke. N Engl J Med 343: 317–326.
15. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, et al. (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368: 1155–1163.
16. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288: 2998–3007.

17. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623–1630.

18. Hitman GA, Colhoun H, Newman C, Szarek M, Betteridge DJ, et al. (2007) Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med 24: 1313–1321.

19. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559.

20. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, et al. (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The CARE Investigators. Circulation 99: 216–223.

21. Heart Protection Study Collaborative G (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.

22. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, et al. (2002) Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106: 1690–1695.

23. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, et al. (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357: 2248–2261.

24. Everett BM, Glynn RJ, MacFadyen JG, Rivkier PM (2010) Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 121: 143–150.

25. Wanner C, Krane V, Marz W, Olschewski M, Maun JF, et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248.

26. Felsstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, et al. (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395–1407.

27. Abedini S, Holme I, Feltstrom B, Jardine A, Cole E, et al. (2009) Cerebrovascular events in renal transplant recipients. Transplantation 87: 112–117.

28. Vaughan GJ, Delanty N (1999) Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30: 1969–1973.

29. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M (2003) HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 34: 1298–1300.

30. Amarenco P, Lavallée P, Touboul PJ (2004) Stroke prevention, blood cholesterol, and statins. Lancet Neurol 3: 271–278.

31. Willey JZ, Eldland MS (2010) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 67: 1062–1067.

32. Rysz J, Arenson WS, Stolarz RS, Hannam S, Mikhailidis DP, et al. (2009) Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 13: 541–550.

33. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.

34. Lakhan SE, Bagchi S, Hofer M (2010) Statins and clinical outcome of acute ischemic stroke: a systematic review. Int Arch Med 3: 22.

35. Goldstein LB, Amarenco P, Szarek M, Callahan A, 3rd, Hennerici M, et al. (2008) Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70: 2364–2370.